Highlights Galmed Pharmaceuticals Ltd.

Equities

GLMD

IL0011313900

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-17 pm EDT			5-day change	1st Jan Change
0.405 ^USD	+1.50%		+1.68%	-10.99%

Apr. 04	Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 15	Galmed Pharmaceuticals Ltd. Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of Nash and Liver Fibrosis	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 04	CI
Galmed Pharmaceuticals Ltd. Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of Nash and Liver Fibrosis	Mar. 15	CI
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 22	CI
Galmed Pharmaceuticals Expects Minimum Six Months Delay in Primary Sclerosing Cholangitis Study	Nov. 20	MT
Galmed Pharmaceuticals Ltd. Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis	23-09-26	CI
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-06-01	CI
Galmed Pharmaceuticals Ltd. Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis	23-05-09	CI
Galmed Pharmaceuticals Forms a Strategic Partnership with OnKai	23-05-04	CI
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Galmed Pharmaceuticals Receives US Patent for Aramchol Meglumine Salt	23-02-08	MT
Galmed Pharmaceuticals Ltd. Announces Issuance of New Composition of Matter Patent for Aramchol Meglumine Salt	23-02-08	CI
Galmed Pharmaceuticals Ltd. Reports Results from the Open-Label Part of the Armor Study Showing Improvements in Histology, Imaging, and Biomarkers with Aramchol	23-01-04	CI
Galmed Pharmaceuticals Gets Extension to Regain Compliance With Nasdaq's Bid Price Requirement	22-12-15	MT
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-16	CI
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-04	CI
Galmed Pharmaceuticals Ltd. Reports Significant Anti-Fibrotic Effects of Aramchol in A Lung Fibrosis Model	22-07-07	CI
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-17	CI
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-05-02	CI
Galmed Pharmaceuticals Ltd. Reports Interim Results from the Open-Label Part of the Armor Study with Aramchol Showing Robust Fibrosis Improvement Across Multimodality Histological Assessment	22-04-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Galmed Pharmaceuticals Ltd.

Equities

GLMD

IL0011313900

Highlights

Filters